Kevin Holcomb

38 M.D. Director, Division of Gynecologic Oncology – Beth Israel Medical Center, New York City

Kevin Holcomb, M.D., wears many hats?husband, father of two ?beautiful children,? director of gynecologic oncology at Beth Israel Medical Center and assistant clinical professor of obstetrics and gynecology at Columbia University College of Physicians and Surgeons. Passionate about his work, he has contributed significantly to research in the management of cervical cancer and the treatment of cervical precancer in HIV-positive women. And, as a member of the Harlem Cancer Control Coalition, he is seeking clarification of the extent and causes of racial health-care disparities in the New York area and promoting heightened cancer screening and the benefits of early detection.

All that notwithstanding, he finds time to serve on the board of directors of the American Cancer Society, on the executive council of the Metropolitan Gynecologic Cancer Society and to be a member of organizations such as Kappa Alpha Psi and the Westchester Boule of Sigma Pi Phi fraternities. In recognition of his dedication to his students and residents, he received a National Faculty Teaching Award in 2002 and 2004 from the Council on Residency Education in Obstetrics and Gynecology.

It all adds up to success. ?I attribute my success to God for blessing me with the opportunity to pursue my dreams, my parents for teaching me that my dreams can be realized through hard work and dedication and my wife, Kareen, for being my soul mate, friend and unwavering supporter,? Holcomb says. ?Our main anxiety does not empty tomorrow of its success, but only empties today of its strength,? he adds, quoting his favorite saying.

Holcomb graduated from Cornell University and New York Medical College and was a resident in obstetrics and gynecology at New York Hospital/Cornell Medical Center. He earned a fellowship in gynecologic oncology at SUNY-Downstate Medical Center in Brooklyn, N.Y. ?I would love to bring the skills I have learned in the U.S.A. to developing nations where potentially curable malignancies continue to kill millions,? he says.